UHS

Business Context and Reporting Period

Company: Universal Health Services, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2003
Business Overview: The Company operates acute care hospitals, behavioral health care facilities, and international acute care hospitals (primarily in France). Operations are segmented into Acute Care Hospital Services, Behavioral Health Services, International Acute Care Hospital Services, and Other (centralized services and outpatient centers).

Key Financial Metrics

Note: Total Debt calculated as Current maturities of long-term debt ($11,092) plus Long-term debt, net of current maturities ($730,600) as of March 31, 2003.

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 11% ($91 million) year-over-year. This was driven by an 8% increase in revenues from existing facilities, $14 million from new acquisitions (Alaska behavioral health system and French hospitals), and $16 million from other increases including reclassifications related to French GAAP conversion.
• Profitability: Operating income rose 13% to $149 million. Operating margins improved to 16.6% from 16.3%, primarily due to a decrease in other operating expenses (down to 22.8% of revenue) driven by a new pharmacy outsourcing agreement.
• Segment Performance:
  • Acute Care: Same-facility revenues increased 8% with a 1.9% rise in admissions, though patient days decreased 0.7% due to shorter average length of stay (4.7 days vs. 4.8 days).
  • Behavioral Health: Revenues increased 4% with higher admissions and patient days. Operating margins improved to 21.9% from 20.5%.
• Acquisitions and Dispositions: The Company spent $45.5 million on acquisitions (Alaska behavioral health, two French hospitals, Oklahoma surgery center) and received $3.0 million from the sale of two radiation therapy centers.

Guidance, Outlook, Risks, and Contingencies

• Capital Expenditures: The Company spent $40.3 million in Q1 2003. It expects to spend an additional $180 million to $190 million for the remainder of 2003, totaling approximately $220 million to $230 million for the full year. Major projects include a new hospital in Las Vegas and expansions in Texas and Florida.
• Acquisition Pipeline: Agreements are in place for approximately $125 million in additional acquisitions during 2003, subject to conditions.
• Liquidity: The Company has $309 million of unused borrowing capacity under a $400 million revolving credit agreement. Commercial paper capacity was fully utilized as of March 31, 2003.
• Insurance and Liability Risks:
  • The Company is self-insured for malpractice up to $25 million per occurrence due to unfavorable commercial insurance markets.
  • Total accrual for professional and general liability claims (including PHICO-related claims) was $165.7 million ($128.7 million net of expected recoveries).
  • PHICO liquidation remains a contingency; while a $40 million charge was recorded in 2001, ultimate liability could differ materially.
• Regulatory and Reimbursement Risks:
  • Significant revenue reliance on Medicare/Medicaid (39% of net patient revenues) and managed care (40%).
  • Concerns regarding potential reductions in Medicaid reimbursements, particularly in Texas and South Carolina (DSH funds).
  • Implementation of HIPAA security standards and potential changes to Medicare outlier payment formulas.
• SEC Inquiry: The Company disclosed an informal inquiry by the SEC Philadelphia District Office regarding the departure of the former Chief Financial Officer, Kirk Gorman.

Investor Verification Checklist

• Insurance Reserves: Verify the adequacy of the $165.7 million liability reserve, specifically regarding the uncertainty of PHICO-related claims and potential state guaranty fund recoveries.
• Reimbursement Trends: Monitor the impact of the Texas Medicaid DSH program review and potential overpayment findings on future cash flows.
• Acquisition Integration: Assess the financial performance of the newly acquired Alaska behavioral health system and French hospitals to ensure they meet projected returns.
• Capital Allocation: Track the execution of the $220-$230 million capital expenditure plan and the $125 million pending acquisition pipeline against available liquidity.
• Regulatory Compliance: Review updates on the SEC inquiry and the Company's compliance with evolving HIPAA and Medicare payment regulations.